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Jeffrey Schriber,1 Manza-A. Agovi,2 Vincent Ho,3 Karen K. Ballen,4 Andrea Bacigalupo,5
Hillard M. Lazarus,6 Christopher N. Bredeson,7 Vikas Gupta,8 Richard T. Maziarz,9
Gregory A. Hale,10 Mark R. Litzow,11 Brent Logan,2 Martin Bornhauser,12 Roger H. Giller,13
Luis Isola,14 David I. Marks,15 J. Douglas Rizzo,2 Marcelo C. Pasquini2Failure to engraft donor cells is a devastating complication after allogeneic hematopoietic cell transplantation
(HCT). We describe the results of 122 patients reported to the National Marrow Donor Program between
1990 and 2005, who received a second unrelated donor HCTafter failing to achieve an absolute neutrophil
count of$500/mL without recurrent disease. Patients were transplanted for leukemia (n5 83), myelodysplas-
tic disorders (n5 16), severe aplastic anemia (n5 20), andotherdiseases (n5 3). Themedian agewas 29 years.
Twenty-four patients received second grafts from a different unrelated donor. Among 98 patientswho received
a secondgraft from the samedonor, 28 receivedproducts thatwerepreviously collected andcryopreserved for
the first transplantation. One-year overall survival (OS) after second transplant was 11%, with 10 patients alive
at last follow-up.We observed no differences between patients who received grafts from the same or different
donors, or in those who received fresh or cryopreserved product. The outcomes after a second allogeneic
HCT for primary graft failure are dismal. Identifying risk factors for primary graft failure can decrease the
incidence of this complication. Further studies are needed to test whether early recognition and hastened
procurement of alternative grafts can improve transplant outcomes for primary graft failure.
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Primary graft failure after hematopoietic cell trans-
plantation (HCT) is a life- threatening complication
whose reported incidence is as high as 11% [1-3].
Treatment approaches including growth factors,
manipulation of immunosupressant doses, or infusion
of additional autologous or allogeneic stem cells with
or without preparative regimens are among the
strategies that have been attempted to overcome
nonengraftment [4]. Unfortunately, available data on
outcomes after a subsequent transplantation for treat-
ment of primary graft failure is limited and heteroge-
neous. Studies published to date commonly combine
primary and secondary graft failures, related and unre-
lated donors, and often include second transplants for
treatment of early posttransplant relapse [5-16].
Patients with primary graft failure typically have
a number of high risk factors, which makes a second
transplant challenging. These include being pancyto-
penic for weeks, often with active infections and poor
performance status.Furthermore, recipients of unrelated
donor grafts face additional logistic challenges with
donor procurement, not seen with sibling transplants.
This may not only prolong the time to the second1099
Figure 1. Selection criteria and study population according to donor type and graft source status. Abreviations: DLI, donor lymphocyte infusion; HCT,
hematopoietic cell transplantation; UCD, umbilical cord blood; URD, unrelated donor.
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volunteer donors.
Considering the emotional and financial burden
on patients, their families, transplant centers, as well
as the resources required for donor procurement for
subsequent transplantation, it is important to charac-
terize the outcomes carefully. Here, we describe the
results of 122 patients reported to the National
Marrow Donor Program (NMDP), which received
second unrelated donor transplantation for treatment
of primary graft failure.METHODS
Data Sources
This observational study uses data from the Center
for International Blood and Marrow Transplant
Research (CIBMTR) database on unrelated donor
transplants facilitated by the NMDP. The CIBMTR
comprises a voluntary working group of more than
450 transplantation centers worldwide that contribute
detailed data on consecutive HCT to a Statistical Cen-
ter at the Medical College of Wisconsin in Milwaukee
and the NMDP Coordinating Center in Minneapolis.
Participating centers are required to report all trans-
plants consecutively; compliance is monitored by
on-site audits. The CIBMTR maintains an extensive
database on detailed patient-, transplant-, and
disease-related information for transplants performed
worldwide, and prospectively collects data longitudi-
nally with yearly follow-ups. Computerized checks
for discrepancies, physicians’ review of submitted
data, and on—site audits of participating centers ensure
data quality. Observational studies conducted by theCIBMTR are performed in compliance with the
Privacy Rule (HIPAA) as a Public Health Authority,
and in compliance with all applicable federal regula-
tions pertaining to the protection of human research
participants as determined by continuous review of
the institutional review boards of the National Marrow
Donor Program and the Medical College of Wisconsin
since 1985.Patient Population
We reviewed the records of 14,564 patients
reported from 1990 to 2005, who underwent an
unrelated bone marrow (BM) or mobilized peripheral
blood progenitor cells (PBPC) HCT, facilitated by the
NMDP. Nine hundred eighty-one patients (6.7%)
were reported by the transplant center as having
primary graft failure, that is, not achieving a minimum
absolute neutrophil count (ANC) of 500/mL without
evidence of disease relapse (Figure 1). Among the
817 patients with primary graft failure who had no
information on second transplants, 808 (99%) died
within the first year, with the majority (N5 707) dying
within 30 days from the first HCT; 7 patients were lost
to follow-up, but were alive 1 year after transplanta-
tion, and 2 patients died 3 years after transplant.
Among 164 patients who received a second HCT,
122 received BM or PBPC grafts from unrelated do-
nors, 26 from a previously cryopreserved autologous
graft, 10 from a related donor, 4 received an umbilical
cord blood graft, and 2 patients received donor lym-
phocyte infusion (DLI).
Patients who had evidence of engraftment prior to
the second HCT, who received umbilical cord blood
grafts or DLIs, or patients who had a period .180
days between the HCTs were excluded. Data on the
Table 1. Demographic and Disease Characteristics of
Patients Who Received a Second Unrelated Hematopoietic
Cell Transplantation for PrimaryGraft FailureReported to the
NMDP 1990 and 2005
Characteristics of Patients N Eval N (%)
Patient related:
Number of patients 122
Age, median (range), years* 122 30 (2-62)
#20 41 (33)
21-40 45 (38)
>40 36 (18)
Male sex 122 79 (65)
Disease related:
Disease Indication for first transplant 122
Acute myelogenous leukemia 18 (15)
Acute lymphoblastic leukemia 13 (11)
Other leukemia† 3 (2)
Chronic myelogenous leukemia 49 (40)
Myelodysplastic/myeloproliferative
disorders
16 (13)
Severe aplastic anemia 20 (16)
Other nonmalignant indications‡ 3 (1)
Disease status prior to first transplant 122
Early 51 (42)
Intermediate 26 (21)
Advanced 14 (11)
Non-malignant 23 (19)
Unknown§ 8 (7)
Time from diagnosis to first transplant,
median (range), months
121 13 (2-175)
Time from first transplant to second
transplant, median (range), days
122 48 (18-126)
Year of second transplant 122
1990-1992 8 (7)
1993-1995 32 (26)
1996-1998 28 (23)
1999-2001 27 (22)
2002-2004 18 (15)
2005 9 (7)
Donor age for second transplant,
median (range), years
122 37 (19-59)
Number of total transplants 122
2 110 (90)
3 11 (9)
Median follow-up of survivor after
second transplant, (range) months
10 77 (2-144)
†Juvenile chronic myelogenous leukemia (n5 1), acute undifferentiated
leukemia (n 5 1), and chronic lymphocytic leukemia (n 5 1).
‡Primary immunedeficiency (n5 1), congenital platelet disorder (n5 1),
and histiocytic disorder (n5 1).
§Juvenile chronic myelogenous leukemia (n 5 1), acute undifferentiated
leukemia (n 5 1), chronic lymphocytic leukemia (n 5 1), myelofibrosis
with myeloid metaplasia (n 5 4), and paroxysmal nocturnal hemoglobin-
uria (n5 1).
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lated donor, reported from 47 centers worldwide, were
analyzed for this study.Outcomes
Outcomes analyzed include 30-day and 100-day
mortality, overall survival (OS), neutrophil engraft-
ment, disease-free survival (DFS), treatment-related
mortality (TRM), and relapse for patients with malig-
nant diseases. Disease relapse was defined as clinical or
hematologic evidence of disease recurrence. DFS was
analyzed as time from second HCT to relapse or deathfrom any cause. For analysis of OS, failure was death
from any cause; surviving patients were censored at
date of last contact. Time to neutrophil engraftment
was defined as the time to achieve a sustained ANC
of $500 cells/mL for 3 consecutive days after the
second transplant.
Statistical Analysis
Probabilities of DFS, OS, and 30-day and 100-day
mortality were calculated using the Kaplan-Meier
estimator, with the variance estimated by the Green-
wood’s formula. Probabilities of TRM, relapse, neu-
trophil engraftment were calculated using cumulative
incidence rates to accommodate for competing risks.
All computations were performed using the statistical
package SAS version 9.1.RESULTS
Patient Characteristics
Patient characteristics and demographics are sum-
marized in Table 1. The median age at time of second
HCT was 30 years (range: 2-62) and one-third of the
patients were #20 years of age. Karnofsky perfor-
mance scores (KPS) were available on 63 patients at
the time of second HCT. Of these, 62% had a KPS
of #50. Most patients had acute leukemia as their pri-
mary diagnosis. The median time from first to second
HCT was 48 days, with a range of 18 to 126 days.
Eighty-seven percent of patients received an ablative
conditioning regimen for the first HCT (Table 2). De-
tails on the conditioning regimen for the second trans-
plant are unavailable in 23% of patients. Among
patients with available conditioning regimen data for
second HCT, 38% received a myeloablative condi-
tioning regimen and 11% received no conditioning
regimen. Thirty-one percent of patients received an-
tithymocyte globulin (ATG) as part of the first
HCT, whereas 61% of patients with available data re-
ported use of ATG for the second HCT. T cell-
depleted grafts were used in 42% and 10% of patients
for the first and second HCT, respectively. The me-
dian follow-up of survivors from the second HCT
was 77 months (range: 2-144) (Table 2).
Graft Source Type and Cell Dose
Bone marrow was the graft source in 51% of
second HCT and 84% of first HCT. Ninety-eight pa-
tients received a second HCT from the same donor,
whereas 24 patients had a different unrelated donor.
Among patients who received cells from the same do-
nor, 28 patients received a cryopreserved product. The
median nucleated cell dose infused was 2.5  108/kg
for both first and second HCT, although data was
missing in 27% of patients for the second transplant.
Table 2. Transplant Characteristics from the First and Second Transplant in Patient Who Received Second Unrelated Donor
Hematopoietic Cell Transplantation for Treatment of Graft Failure
First Transplant Second Transplant
Transplant Characteristics N Eval N (%) N Eval N (%)
Nucleated cell dose, median
(range), 108/kg*
121 2 (<1-23) 122 2 (<1-50)
<2.5 74 (60) 48 (39)
2.5-4.5 29 (24) 24 (20)
$4.5 18 (15) 17 (14)
Missing 1 (<1) 33 (27)
Preparative regimen type 122 122
Myeloablative 106 (87) 36 (30)
Nonmyeloablative/RIC 16 (13) 44 (36)
No conditioning received — 14 (11)
Missing — 28 (23)
ATG-based conditioning 122 80
Yes 38 (31) 49 (61)
No 84 (69) 31 (39)
Conditioning regimen 122 122
Cy + TBI ± other 61 (50) 5 (4)
Bu + Cy ± other 38 (31) —
Bu ± other 2 (2) —
Cy ± other 9 (7) 33 (27)
Fludarabine ± other 12 (10) 24 (20)
ATG ± other — 15 (12)
Other† — 2 (2)
None — 15 (11)
Missing — 28 (23)
HLA match‡ 122 122
Well matched 19 (16) 14 (12)
Partially matched 50 (41) 53 (43)
Mismatched 53 (43) 52 (43)
Non evaluable — 3 (2)
ABO compatibility at transplant§ 121 121
Major ABO-incompatible 38 (31) 37 (31)
Minor ABO-incompatible 33 (27) 30 (25)
Matched ABO 50 (41) 54 (44)
Graft-versus-host disease prophylaxis 122 94
T cell depletion 51 (42) 9 (10)
Cyclosporine + methotrexate ± other 42 (35) 18 (19)
CNI + mycophenolate 9 (8) 14 (15)
Cyclosporine only 6 (5) 25 (26)
Tacrolimus + methrotrexate ± other 14 (4) 4 (4)
Other¶ — 17 (19)
None — 7 (7)
Graft type 122 122
Bone marrow 102 (84) 62 (51)
Peripheral blood 20 (16) 60 (49)
HLA indicates human leukocyte antigen; RIC, reduced-intensity conditioning; GVHD, graft-versus- host disease; ATG, antithymocyte globulin; TBI, total
body irradiation; Bu, busulfan; Cy, cyclophosphamide; CNI, calcineurin inhibitor.
*Continuous variables, median (range).
†Otherconditioning regimen: corticosteriods+ total lymphoid irradiation+monoclonal antibody (n51),methylprednisolone+monoclonal antibody (n5 1).
‡Well matched was defined as no known disparity at HLA-A, -B, -C, -DRB1, partially matched as 1 locus known or likely disparity with their donors, and
mismatched as $2 locus disparity.
§According to published definition [20].
¶Other GVHD prophylaxis: tacrolimus (n 5 9), corticosteroids + ATG (n 5 1), corticosteroids only (n 5 3), and other non specified (n 5 4).
1102 Biol Blood Marrow Transplant 16:1099-1106, 2010J. Schriber et al.Engraftment
Complete report information on engraftment after
second HCT was only available on 79 patients. The
cumulative incidence (CI) for neutrophil engraftment
at 28 and 100 days was 66% [95% CI, 55-76] and
74% (95% CI, 64-84), respectively (Figure 2).Survival Outcomes and Relapse
The 30-day and 100-day mortality rates were 39%
(95% CI, 31-48) and 75% (95% CI, 67-82), respectively.Among patients with malignant disease, TRM, relapse,
and DFS at 1 year after second HCT were 86% (95%
CI, 79-92), 7% (95%, CI 2-12), and 7% (95% CI,3-
12), respectively (Table 3). Ten patients (8%) were alive
and disease free at time of last follow-up (Figure 3). Pa-
tients who failed to engraft after the second transplant
had a median survival of less than 1 month. Univariate
comparisons of post transplant outcomes were similar
between same versus different donor, fresh versus cryo-
preserved grafts, and cell doses below versus above the
median cell dose infused (Table 4).
Figure 2. Neutrophil engraftment after second unrelated donor hematopoietic cell transplantation for primary graft failure.
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Table 5 shows the causes of death, reported to the
CIBMTR by the treating center, in patients who un-
derwent a second transplant. Graft failure was consid-
ered the primary cause of death for 38 patients (34%).
Among 32 of the reported 38 patients, who died of
graft failure and had available information on second-
ary causes of death, 57% died from an infection-
related cause. Infection without graft failure was the
reported cause of death in 17 (15%) patients. Other
reported causes of death include end organ failure
(15%), graft-versus-host disease (GVHD) (13%), idio-
pathic pneumonia syndrome (9%), and hemorrhage
(4%), among others. Together, graft failure and
infection accounted for 47% of all deaths.Table 3. Univariate Probabilities of Outcomes after Second
Unrelated Donor Hematopoietic Cell Transplantation for
Primary Graft Failure
Outcome of Interest N Eval Probability (95% CI)
*Treatment-related mortality
@ 1 year
99 86 (79-92) %
*Relapse @ 1 year 99 7 (3-13) %
*Disease-free survival @ 1 year 99 7 (2-12) %
30-day mortality 48/121 39 (31-48) %
100-day mortality 91/122 75 (67-82) %
Overall survival
@ 6 months 122 13 (9-20) %
@ 1 year 122 11 (6-17) %
CI indicates confidence interval.
*Treatment-related mortality, relapse, and disease-free survival were
only calculated for patients with malignant disease (N5 99). These dis-
eases include acute myelogenous leukemia, acute lymphoblastic leuke-
mia, chronic mylogenous leukemia, and myelodysplastic syndrome.DISCUSSION
This study presents the largest experience to date
of a second transplant with unrelated donor grafts as
salvage in patients with primary graft failure without
disease relapse. The incidence of primary graft failure
in this cohort of patients who received unrelated donor
HCT from 1990 to 2005 is 6.7%. Interestingly, this
incidence decreased during the 15-year study period
with 8.2%, 6.9%, and 3.6% of patients experiencing
this complication from 1990 to 1995, 1996 to 2000,
and 2001 to 2005, respectively. Improvements in
HLA matching with utilization of high-resolution
typing and better donor selection or the increased
use of PBPC may account for the drop of primary graft
failure incidence over time.
Survival after a second unrelated donor HCT as
a rescue from initial nonengraftment is dismal, with
only 11% of patients being alive and disease free at
1 year. The results suggest that this strategy as cur-
rently practiced is ineffective. Moreover, this group
represents a small minority of those 981 patients who
were identified by the treating center as having
primary graft failure. The 1-year OS of the 981 with
primary graft failure after the first HCT is\1%.
Results from this study are similar to previous
published reports. It is important to highlight that
cross-study comparisons are difficult based on the het-
erogeneity of study populations. The French multi-
center study analyzed the outcomes of second HCT
for graft failure in 82 patients with malignant diseases
and severe aplastic anemia [8]. Twenty-eight patients
had primary graft failure as defined in this study, and
12 patients received an unrelated donor graft. Median
survival of this population was 3 months and estimated
3-year survival was 30%. The study did not analyze
primary graft failure, which generally has a worse
prognosis separately. The German Bone Marrow
Figure 3. Probability of OS after second allogeneic unrelated donor transplant for ‘‘nonengraftment.’’
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with malignant diseases undergoing a second unre-
lated donor HCT for primary graft failure (N 5 34)
or disease relapse (N 5 36) [11]. Half of the patients
with primary graft failure received no conditioning
prior to a second transplant, and virtually all received
PBPC as the graft source for their second transplant.
There was no benefit noted for those patients receiving
prior conditioning versus stem cell infusion alone. The
OS after the second HCT for primary graft failure was
37%, with a median follow-up of 33 months. Patients
older than 50 years of age faired particularly poorly
with only 8% surviving in the first year after the second
transplantation. Although the estimated OS was supe-
rior to this report, the median survival was\5 months.
The French study also demonstrated that patients
younger (age\34 years) were twice as likely to be alive
at 3 years from the second HCT [8]. Other smaller
studies suggest better outcomes in the pediatric popu-
lation, with a larger proportion of patients being alive
at 1 year after the second HCT [6,7,13]. In our
analysis, recipient’s age had no impact on survival
outcomes (data not shown).
Additional factors were analyzed to determine
their impact on survival, and showed no differences,Table 4. Overall Survival Probabilities after a Second Unrelated D
Failure According to Graft Status and Donor Type
N Eval
Fresh Original Second Donation
Probability (95% CI)
30
@ 30 days 57 (39-74)%
@ 1 year 14 (4-29)%
Different Donor for Second HCT
24
@ 30 days 58 (48-68)%
@ 1 year 11 (6-18)%
HCT indicates hematopoietic cell transplantation; CI, confidence interval.
*Pointwise P-value.including same or different donor, fresh or cryopre-
served product, and cell dose. Small numbers and
few survivors hinder the identification of subgroups
with better outcomes.
The second HCT successfully reestablished hema-
topoiesis, and the cumulative incidence of neutrophil
engraftment prior to day 100 was 74%. Similar en-
graftment rates were observed in other series of
salvage second transplants, which included related do-
nor transplants [8,13]. It is important to note in the
current study that the mortality rate after neutrophil
engraftment was high. Among 58 patients who
successfully engrafted prior to day 100, 37 died from
the time of engraftment to day 100.
The most common causes of death were directly re-
lated to bone marrow failure, such as infection and hem-
orrhage. Even among those patients who engrafted, the
OS was dismal (19%, 95 CI, 10%-29%), highlighting
the generally poor prognosis of this patient population.
Diagnosis of primary graft failure occurs when
patients failed to engraft within 28 days from stem
cell infusion, and, in our series, the median time to
a second transplant was 48 days. Identification of prog-
nostic factors for primary graft failure might assist with
earlier donor procurement. Leukocyte count #200/onor Hematopoietic Cell Transplantation for Primary Graft
N Eval
Cryopreserved Second Donation
Probability (95% CI) P-Value*
28
61 (42-78)% 754
7 (1-19)% 389
Same Donor for Second HCT
98
71 (52-87)% 237
8(1-22)% 635
Table 5. Causes of Death after Second Unrelated Donor
Hematopoietic Cell Transplantation for Primary Graft Failure
Causes of Death N (Eval) N (%)
Number of patients 112
Graft rejection/failure* 38 (34)
Infection 17 (15)
Organ failure 17 (15)
GVHD 15 (13)
Idiopathic pneumonia syndrome 10 (9)
Primary disease 7 (6)
Hemorrhage 4 (4)
Other† 4 (4)
GVHD indicates graft-versus-host disease.
*Secondary causes of death to primary graft failure/rejection where
available (n 5 32): fungal infection (n 5 12), bacterial infection (n 5 6),
pneumonia (n5 3), acute respiratory distress syndrome (n5 2), pulmo-
nary toxicity (n5 2), renal failure (n5 2), secondary malignancy (n5 1),
hemorrhage (n5 2), sinusoidal obstructive syndrome (n5 1), and other
infection (n5 1).
†Other causes of death: encephalitis (n 5 1), myocardial infarction
(n 5 1), other toxicities (n 5 1), and cardiopulmonary arrest (n 5 1).
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ful predictor for primary graft failure [17]. Identifica-
tion of other predicators for graft failure have the
potential to significantly alter the median time to sec-
ond transplant, which may lead to earlier engraftment,
reducing the pancytopenic period and mortality re-
lated to infection.
Utilization of a backup product, that is, autologous
or unrelated cord blood, is another strategy to reduce
time to graft procurement, although the data remains
limited. Practices of storing an autologous product as
a backup prior to an unrelated donor HCT are
common in Europe [18] . Analysis of 25 patients who
received autologous backup for treatment primary
graft failure resulted on a 16% 1-year OS [15]. Among
the patients reported to the NMDP, 26 received
a backup autologous graft, 24 of whom died within
6 months of their second transplant. Two patients
with chronic myelogenous leukemia remain alive 158
and 14 months following the second transplant. Small
series have looked at umbilical cord blood as salvage
for graft failure. One report, 3 of 4 patients were alive
beyond 12 months after salvage transplant using dou-
ble cord units [19]. In 4 of such patients reported to the
CIBMTR, 2 were alive at 12 and 5 months posttrans-
plant. It might be advantageous to have cord blood
units identified early in the process as a backup for po-
tential use.
Patients who have primary graft failure represent
a very complex problem. Most patients will die before
being able to receive a second HCT. Our study
suggests that, in practice, primary graft failure is an
uncommon complication, and it is decreasing in recent
years. Survival after the second transplant for primary
graft failure remains unacceptably poor, and
despite retransplantation, nearly all patients died of in-
fections and complications of prolonged pancytopenia.
Strategies to improve outcomes include identifyingrisk factors for primary graft failure to potentially
avoid this complication and using early predictors for
graft failure to initiate early procurement of alternative
grafts to be used for salvage.ACKNOWLEDGMENTS
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